

Polyclonal Antibody to TET2 (N-term) - Aff - Purified

Alternate names:	KIAA1546, Methylcytosine dioxygenase TET2
Catalog No.:	TA319944
Quantity:	0.1 mg
Concentration:	1.0 mg/ml
Background:	TET2, a member of the ten-eleven-translocation (TET) family of genes, is a methylcytosine dioxygenase that catalyzes the conversion of methylcytosine to 5-hydroxymethylcytosine. It is a candidate tumor suppressor gene reported to be mutated in approximately 14% of patients with JAK2V617F-positive myeloproliferative neoplasms, and can be mutated in other hematopoietic disorders such as myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. Analysis of the TET2 and JAK2 mutations in these neoplasms suggests that mutations in TET2 do not represent a predisposition for acquiring mutations in JAK2.
Uniprot ID:	Q6N021
NCBI:	NP_001120680
GeneID:	54790
Host / Isotype:	Rabbit / IgG
Immunogen:	18 amino acid synthetic peptide near the amino terminus of Human TET2 (AP55673CP-N)
Format:	State: Liquid purified Ig fraction Purification: Affinity chromatography purified via peptide column Buffer System: PBS containing 0.02% Sodium Azide as preservative
Applications:	Western blot: 1-2 µg/ml. <i>Positive Control:</i> SK-N-SH cell lysate. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Specificity:	This antibody will detect both isoforms (at least two isoforms of TET2 are known to exist).
Species Reactivity:	Tested: Human.
Add. Information:	Blocking peptide available: AP55673CP-N
Storage:	Store undiluted at 2-8°C for one month or (in aliquots) at -20°C for longer. Avoid repeated freezing and thawing. Shelf life: one year from despatch.
General Readings:	1. Tefferi A, Levine RL, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, et al. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRα correlates. <i>Leukemia</i> . 2009 May;23(5):900-4. doi: 10.1038/leu.2009.37. Epub 2009 Mar 5. PubMed PMID: 19262599. 2. Schaub FX, Looser R, Li S, Hao-Shen H, Lehmann T, Tichelli A, et al. Clonal analysis of

TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood. 2010 Mar 11;115(10):2003-7. doi: 10.1182/blood-2009-09-245381. Epub 2010 Jan 8. PubMed PMID: 20061559.

Pictures:

Western blot analysis of TET2 in SK-N-SH cell lysate with TET2 antibody at 1 ug/mL.

